11-28-2018 05:01 PM CET - Health & Medicine
Print

Global Vitiligo Market by Countries, Drugs, Companies, Clinical Study, Growth Drivers & Challenges

Press release from: Renub Research
global-vitiligo-market-countries-companies-growth-drivers-challenges
global-vitiligo-market-countries-companies-growth-drivers-challenges


Access full Research:
www.renub.com/global-vitiligo-market-p.php

Get Free Customization in This Report

Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from sun UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, shortage of dermatologists and available treatments having longer duration of times are major challenges for the growth of this market. According to Renub Research global Vitiligo market will be US$ 2.4 Billion by the year 2024.

Vitiligo disease prevalence varies between race, regions and countries. It is expected that overall prevalence fall between 1-2 percent of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million people has suffered from this diseases. There are number of drugs manufactures working for Vitiligo drugs development across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc. and their Vitiligo drugs development are in various stages.

Request a free sample copy of the report: www.renub.com/contactus.php

Renub Research report titled “Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges” provides a complete analysis of global vitiligo drugs market.

India and China are Key Contributors in the Global Vitiligo Patient Population
Vitiligo patient’s population is growing across all parts of the world. Patient’s growth rates varies in the countries covered in the report United States, United Kingdom, France, Germany, Italy, India, China and Japan. India and China are key contributors in the global vitiligo patient population.

Vitiligo Pipe Line Drugs are Key Strength for this Market Place
In the global vitiligo market, vitiligo pipe line drugs will play the major role for the growth of this market. At present several drugs such as ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.

Key Drugs Development Companies are working in this Market Place
Key drugs development companies are working in this market place across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc.

Segments - Global Vitiligo Market
• Vitiligo Patients Population
• Vitiligo Market

Countries - Global Vitiligo Market
• United States
• United Kingdom
• France
• Germany
• Italy
• India
• China
• Japan

Global Vitiligo Market – Drugs Profile Covered
• ARN-4079
• ATI-502
• AX-1602
• BOS-47
• CCP-070
• Cerdulatinib (RVT-502)
• HuABC-2
• Abatacept
• Topical Ruxolitinib
• VLRX-001

Companies Covered
• AXIM Biotechnologies
• Incyte Corporation
• Bristol-Myers Squibb
• Clinuvel Pharmaceuticals

Each Company Covered in this Report has Following Details
• Company Overview
• Company Initiatives
• Financial Insight

If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com

Contact Us
Email: info@renub.com
Phone: +1-678-302-0700
Web: www.renub.com

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today's ultra-competitive markets.

225 Kristie Ln, Roswell, GA 30076, United States

This release was published on openPR.
News-ID: 1404368 • Views: 164
More releasesMore releases

You can edit or delete your press release here: